Market closed
Aligos Therapeutics/$ALGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
$ALGS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
70
Website
ALGS Metrics
BasicAdvanced
$31M
-
-$20.94
2.52
-
Price and volume
Market cap
$31M
Beta
2.52
52-week high
$46.80
52-week low
$4.81
Average daily volume
178K
Financial strength
Current ratio
2.859
Quick ratio
2.619
Long term debt to equity
-16.971
Total debt to equity
-28.906
Management effectiveness
Return on assets (TTM)
-50.29%
Return on equity (TTM)
-415.84%
Valuation
Price to revenue (TTM)
8.019
Price to book
-0.67
Price to tangible book (TTM)
-0.67
Price to free cash flow (TTM)
-0.391
Growth
Revenue change (TTM)
-74.60%
Earnings per share change (TTM)
-38.76%
3-year revenue growth (CAGR)
-3.27%
3-year earnings per share growth (CAGR)
-36.16%
ALGS News
AllArticlesVideos
Aligos Therapeutics Presents Positive Data at APASL 2025
GlobeNewsWire·2 weeks ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $31M as of April 08, 2025.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of April 08, 2025.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) has a beta rating of 2.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.